Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
Yun Bian, Maoyun Sun, Marcy Silver et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2009
Neuregulin-1 (NRG1) is a potential therapeutic agent for the treatment of doxorubicin (Dox)-induced heart failure. NRG1, however, activates the erbB2 receptor, which is frequently overexpressed in breast cancers. It is, therefore, important to understand how NRG1, via erbB2, protects the heart against Dox cardiotoxicity. Here, we studied NRG1-erbB2 signaling in Dox-treated mice hearts and in isolated neonatal rat ventricular myocytes (NRVM). Male C57BL/6 mice were treated with recombinant NRG1 before and daily after a single dose of Dox. Cardiac function was determined by catheterization. Two-week survival was analyzed by the Kaplan-Meier method. Cardiac troponins [cardiac troponin I (cTnI) and cardiac troponin T (cTnT)] and phosphorylated Akt protein levels were determined in mice hearts and in NRVM by Western blot analysis. Activation of caspases and ubiquitinylation of troponins were determined in NRVM by caspase assay and immunoprecipitation. NRG1 significantly improved survival and cardiac function in Dox-treated mice. NRG1 reduced the decrease in cTnI, cTnT, and cardiac troponin C (cTnC) and maintained Akt phosphorylation in Dox-treated mice hearts. NRG1 reduced the decrease in cTnI and cTnT mRNA and proteins in Dox-treated NRVM. Inhibition of erbB2, phosphoinositide 3-kinase (PI3K), Akt, and mTOR blocked the protective effects of NRG1 on cTnI and cTnT in NRVM. NRG1 significantly reduced Dox-induced caspase activation, which degraded troponins, in NRVM. NRG1 reduced Dox-induced proteasome degradation of cTnI. NRG1 attenuates Dox-induced decrease in cardiac troponins by increasing transcription and translation and by inhibiting caspase activation and proteasome degradation of troponin proteins. NRG1 maintains cardiac troponins by the erbB2-PI3K pathway, which may lessen Dox-induced cardiac dysfunction.
Cited by 82 works. doi:10.1152/ajpheart.01010.2008
Authors
- Maoyun Sun
- Marcy Silver
- Kalon K.L. Ho
- Mark A. Marchionni
- Anthony O. Caggiano
- James R. Stone
- Ivo Amende
- Thomas Hampton
- James P. Morgan
- Xinhua Yan
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Untangling the ErbB signalling network
- The biology of erbB-2/nue/HER-2 and its role in cancer
- USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
- Multiple essential functions of neuregulin in development
- Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
- Anthracycline cardiomyopathy monitored by morphologic changes.
- Structural Aspects of Troponin-Tropomyosin Regulation of Skeletal Muscle Contraction
- Neuregulins Promote Survival and Growth of Cardiac Myocytes